Bispecific antibodies in cancer immunotherapy

ABSTRACTCancer immunotherapyhas recently generated much excitement after the continuing success of the immunomodulating anti- CTLA-4and anti-PD-1 antibodiesagainst various types of cancers. Aside from these immunomodulating antibodies, bispecific antibodies, chimeric antigen receptorT cells, and other technologies are being actively studied. Among the various approaches to cancer immunotherapy, 2 bispecific antibodiesare currently approved for patient care. Many more bispecific antibodiesare now in various phases of clinical development and will become the next generation of antibody-based therapies. Further understanding of immunology and advances in protein engineeringwill help to generate a greater variety of bispecific antibodiesto fight cancer. Here, we focus on bispecific antibodiesthat recruit immune cells to engage and kill tumor cells.